<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849550</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00015605</org_study_id>
    <secondary_id>4265</secondary_id>
    <nct_id>NCT00849550</nct_id>
  </id_info>
  <brief_title>Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.</brief_title>
  <acronym>COBRA</acronym>
  <official_title>A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Hurwitz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche-Genentech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard
      treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the MTD/RPTD of capecitabine/oxaliplatin/bevacizumab/everolimus (XELOX-A-Ev) for subjects with advanced solid tumors.</measure>
    <time_frame>End of treatment phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe dose-limiting and non-dose-limiting toxicities</measure>
    <time_frame>End of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preliminarily investigate the response rate and PFS</measure>
    <time_frame>from response to progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX-A-Ev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)</intervention_name>
    <description>bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral</description>
    <arm_group_label>XELOX-A-Ev</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years or older

          -  Must have a performance status of at least 70% (able to carry on most normal
             activities)

          -  Must have life expectancy of at least 3 months

          -  Must have adequate organ and marrow function as determined by lab tests

          -  Women of child-bearing potential and men must agree to use two forms of contraception

          -  Ability and willingness to sign a written informed consent document

          -  Histologically confirmed solid tumor malignancy that is metastatic or unresectable

        Exclusion Criteria:

          -  Pregnant or breastfeeding and/or lactating women

          -  Patients who have received any other investigational agents within 28 days of the
             first day of study drug

          -  Patients with known CNS metastases

          -  History of other carcinomas within last 5 years (except non-melanoma skin cancer,
             in-situ cervical cancer, localized prostate cancer)

          -  Inadequately controlled hypertension

          -  Significant vascular disease

          -  Invasion or encasement of a major artery

          -  Evidence of bleeding diathesis or coagulopathy

          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to day 1 of study drug

          -  Serious illness or medical condition

          -  History of myocardial infarction, unstable angina, cardiac or other vascular stenting

          -  History of stroke

          -  HIV, Hepatitis C, Hepatitis B or other serious chronic infection

          -  Impairment of Gastrointestinal function or disease

          -  History of interstitial lung disease

          -  Patients who have had radiation therapy, hormonal therapy, biologic therapy or
             chemotherapy for cancer within 28 days of receiving study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Hurwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ingalls Cancer Research Center</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>December 21, 2012</last_update_submitted>
  <last_update_submitted_qc>December 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Herbert Hurwitz</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Cancer</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>XELOX</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>RAD001</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

